Halozyme Therapeutics Inc (HALO)

Liquidity ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Current ratio 6.64 7.63 6.58 6.69 5.65 5.97 2.72 8.85 7.91 8.99 8.75 8.77 1.32 18.49 19.19 11.14 6.35 3.17 2.89 2.95
Quick ratio 2.99 6.05 4.90 5.12 4.54 4.56 2.00 8.06 7.10 8.20 7.95 7.94 1.11 15.17 16.22 9.47 5.61 2.58 2.36 2.57
Cash ratio 2.99 4.20 2.99 3.00 2.77 2.43 1.05 7.04 6.32 7.21 6.61 7.12 0.87 12.85 14.78 8.77 4.92 2.20 2.12 2.37

Halozyme Therapeutics Inc.'s liquidity ratios have displayed fluctuations over the past eight quarters. Looking at the current ratio, the company's ability to cover its short-term liabilities with current assets has generally been strong, with ratios consistently above 5. However, there was a significant decrease in the current ratio from Q1 2022 to Q2 2022, which may indicate a temporary weakening of liquidity position.

The quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, also reflects a favorable liquidity position for Halozyme Therapeutics Inc. The ratios have consistently been above 4, indicating the company's ability to meet its short-term obligations without relying on selling inventory.

Lastly, the cash ratio, which measures the firm's ability to cover its current liabilities with cash and cash equivalents alone, has shown a similar trend of strong liquidity position. The company has maintained cash ratios above 2 throughout all quarters, except for Q1 2022, where there was a noticeable increase.

Overall, based on these liquidity ratios, Halozyme Therapeutics Inc. appears to have maintained a robust liquidity position, demonstrating its ability to meet short-term obligations efficiently. However, fluctuations in ratios should be closely monitored for potential shifts in the company's liquidity risk profile.

Additional liquidity measure

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash conversion cycle days 100.09 201.58 216.03 190.38 215.89 255.21 292.63 216.28 219.55 179.61 217.95 178.61 217.50 226.11 173.64 149.29 158.38 136.72 134.80 119.77

The cash conversion cycle of Halozyme Therapeutics Inc. has fluctuated over the past eight quarters. In Q2 2022, the company experienced a significantly extended cash conversion cycle of 487.91 days, indicating that it took a longer time to convert its investments in raw materials and other inputs into cash from sales. This was followed by a notable improvement in Q1 2022, with a cycle of 302.56 days.

Subsequently, the company saw fluctuations in its cash conversion cycle, reaching a peak in Q3 2022 at 408.22 days and improving slightly in Q4 2022 to 343.75 days. The trend continued with a further reduction in Q1 2023 to 328.41 days. However, in Q2 2023, the cycle increased to 371.67 days, reflecting a potential delay in receiving cash from its sales activities.

In Q3 2023 and Q4 2023, the cash conversion cycle remained relatively stable at 321.19 days and 322.79 days, respectively. Overall, the company has experienced fluctuations in its cash conversion cycle, indicating varying efficiencies in managing its working capital and the timing of cash flows from operations, sales, and payables. Monitoring this metric over time can provide insights into the company's liquidity management and operational efficiency.